NASDAQ:ARQL - ArQule Stock Price, Price Target & More

$2.77 +0.07 (+2.59 %)

(As of 04/25/2018 12:24 PM ET)

Previous Close$2.70

Today's Range$2.70 - $2.85

52-Week Range$0.92 - $3.35

Volume170,760 shs

Average Volume731,506 shs

Market Capitalization$235.20 million

P/E Ratio-6.92

Dividend YieldN/A

Beta0.83

About ArQule (NASDAQ:ARQL)

ArQule, Inc., a biopharmaceutical company, researches and develops therapeutics for the treatment of cancer and rare diseases in the United States. Its lead product candidate is tivantinib (ARQ 197), a small molecule inhibitor of the c-Met receptor tyrosine kinase and its biological pathway, which is in Phase III clinical trial for the treatment of liver cancer. The company's clinical-stage products include ARQ 087, a multi-kinase inhibitor of the fibroblast growth factor receptor (FGFR) family Phase II clinical trial for patients with intrahepatic cholangiocarcinoma and in Phase Ib for multiple oncology indications; ARQ 092, an inhibitor of the AKT serine/threonine kinase in Phase I clinical trials for multiple oncology indications; ARQ 751, a next-generation inhibitor of AKT in Phase I clinical trial for solid tumors; and ARQ 761, an intravenously administered analogue of Beta-lapachone, which is Phase 1b clinical trial used as a promoter of NQo1-mediated programmed cancer cell death. Its pre-clinical development program also includes ARQ 531, an inhibitor of Bruton's tyrosine kinase. The company has co-development and co-commercialization agreement with Daiichi Sankyo Co., Ltd.; license agreement with Kyowa Hakko Kirin Co., Ltd.; and collaborative research and development agreement with Beryllium Development Corp. ArQule, Inc. also has a collaboration agreement with Roivant Sciences Ltd. to develop derazantinib, a pan-FGFR inhibitor in Greater China. The company was founded in 1993 and is headquartered in Burlington, Massachusetts.

Receive ARQL News and Ratings via Email

Sign-up to receive the latest news and ratings for ARQL and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations

Sub-IndustryBiotechnology

SectorMedical

SymbolNASDAQ:ARQL

CUSIP04269E10

Webwww.arqule.com

Phone781-994-0300

Debt

Debt-to-Equity Ratio1.03%

Current Ratio4.98%

Quick Ratio4.98%

Price-To-Earnings

Trailing P/E Ratio-6.92

Forward P/E Ratio-11.54

P/E GrowthN/A

Sales & Book Value

Annual Sales$4.71 million

Price / Sales51.23

Cash FlowN/A

Price / CashN/A

Book Value$0.16 per share

Price / Book17.31

Profitability

EPS (Most Recent Fiscal Year)($0.39)

Net Income$-29,200,000.00

Net MarginsN/A

Return on Equity-247.01%

Return on Assets-79.25%

Miscellaneous

Employees32

Outstanding Shares87,110,000

How to Become a New Pot Stock Millionaire

ArQule (NASDAQ:ARQL) Frequently Asked Questions

What is ArQule's stock symbol?

ArQule trades on the NASDAQ under the ticker symbol "ARQL."

How were ArQule's earnings last quarter?

ArQule, Inc. (NASDAQ:ARQL) announced its earnings results on Monday, March, 5th. The biotechnology company reported ($0.09) earnings per share (EPS) for the quarter, meeting the Zacks' consensus estimate of ($0.09). During the same quarter in the prior year, the business posted ($0.10) earnings per share. View ArQule's Earnings History.

When is ArQule's next earnings date?

ArQule is scheduled to release their next quarterly earnings announcement on Tuesday, May, 1st 2018. View Earnings Estimates for ArQule.

What price target have analysts set for ARQL?

4 Wall Street analysts have issued 12-month target prices for ArQule's shares. Their forecasts range from $4.00 to $6.00. On average, they anticipate ArQule's stock price to reach $5.00 in the next twelve months. View Analyst Ratings for ArQule.

Are investors shorting ArQule?

ArQule saw a increase in short interest during the month of March. As of March 15th, there was short interest totalling 1,599,791 shares, an increase of 128.8% from the February 28th total of 699,076 shares. Based on an average daily trading volume, of 515,326 shares, the days-to-cover ratio is currently 3.1 days. Currently, 2.0% of the shares of the company are sold short.

Who are some of ArQule's key competitors?

Some companies that are related to ArQule include Alder BioPharmaceuticals (ALDR), Flexion Therapeutics (FLXN), Amphastar Pharmaceuticals (AMPH), Assembly Biosciences (ASMB), Inflarx (IFRX), Lexicon Pharmaceuticals (LXRX), Amarin (AMRN), Mirati Therapeutics (MRTX), Eagle Pharmaceuticals (EGRX), Collegium Pharmaceutical (COLL), ARMO BioSciences (ARMO), Urogen Pharma (URGN), Vectura Group (VEGPF), OptiNose (OPTN) and Deciphera Pharmaceuticals (DCPH).

Who are ArQule's key executives?

ArQule's management team includes the folowing people:

Mr. Paolo Pucci, Chief Exec. Officer and Director (Age 57)
Mr. Peter S. Lawrence, Pres, COO & Sec. (Age 55)
Mr. Robert J. Weiskopf, CFO & Treasurer (Age 67)
Dr. Brian Schwartz M.D., Chief Medical Officer (Age 56)
Dawn Schottlandt CFA, Sr. Director of Investor Relations & Corp. Communications

Has ArQule been receiving favorable news coverage?

Headlines about ARQL stock have trended somewhat positive recently, according to Accern. Accern scores the sentiment of news coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. ArQule earned a daily sentiment score of 0.13 on Accern's scale. They also assigned media headlines about the biotechnology company an impact score of 47.19 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the near term.

How do I buy shares of ArQule?

Shares of ARQL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is ArQule's stock price today?

One share of ARQL stock can currently be purchased for approximately $2.77.

How big of a company is ArQule?

ArQule has a market capitalization of $235.20 million and generates $4.71 million in revenue each year. The biotechnology company earns $-29,200,000.00 in net income (profit) each year or ($0.39) on an earnings per share basis. ArQule employs 32 workers across the globe.

How can I contact ArQule?

ArQule's mailing address is ONE WALL STREET, BURLINGTON MA, 01803. The biotechnology company can be reached via phone at 781-994-0300 or via email at [email protected]

MarketBeat Community Rating for ArQule (ARQL)

Community Ranking:		2.6 out of 5 ( )
Outperform Votes:		159 (Vote Outperform)
Underperform Votes:		146 (Vote Underperform)
Total Votes:		305

MarketBeat's community ratings are surveys of what our community members think about ArQule and other stocks. Vote "Outperform" if you believe ARQL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ARQL will underperform the S&P 500 over the long term. You may vote once every thirty days.

ArQule (NASDAQ:ARQL) Price Target and Consensus Rating

(How are Consensus Ratings Calculated?)

4 Wall Street analysts have issued ratings and price targets for ArQule in the last 12 months. Their average twelve-month price target is $5.00, suggesting that the stock has a possible upside of 80.51%. The high price target for ARQL is $6.00 and the low price target for ARQL is $4.00. There are currently 4 buy ratings for the stock, resulting in a consensus rating of "Buy."

	Today	30 Days Ago	90 Days Ago	180 Days Ago
Consensus Rating:	Buy	Buy	Buy	N/A
Consensus Rating Score:	3.00	3.00	3.00	N/A
Ratings Breakdown:	0 Sell Rating(s) 0 Hold Rating(s) 4 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 0 Hold Rating(s) 3 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 0 Hold Rating(s) 1 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 0 Hold Rating(s) 0 Buy Rating(s) 0 Strong Buy Rating(s)
Consensus Price Target:	$5.00	$4.50	N/A	N/A
Price Target Upside:	80.51% upside	69.81% upside	N/A	N/A

ArQule (NASDAQ:ARQL) Consensus Price Target History

Price Target History for ArQule (NASDAQ:ARQL)

ArQule (NASDAQ:ARQL) Analyst Ratings History

Show:

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
4/17/2018	Roth Capital	Boost Price Target	Buy	$5.00 -> $6.00	High
4/5/2018	Leerink Swann	Upgrade	Market Perform -> Outperform		Medium
3/26/2018	B. Riley	Set Price Target	Buy	$4.00	High
12/14/2017	Needham & Company LLC	Upgrade	Hold -> Buy		High

(Data available from 4/25/2016 forward)

ArQule (NASDAQ:ARQL) Earnings History and Estimates Chart

Earnings by Quarter for ArQule (NASDAQ:ARQL)

ArQule (NASDAQ:ARQL) Earnings Estimates

2018 EPS Consensus Estimate: ($0.20)
2019 EPS Consensus Estimate: ($0.34)

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2018	2	($0.05)	($0.05)	($0.05)
Q2 2018	2	($0.09)	$0.05	($0.02)
Q3 2018	2	($0.09)	($0.04)	($0.07)
Q4 2018	2	($0.07)	($0.06)	($0.07)
Q1 2019	1	($0.10)	($0.10)	($0.10)
Q2 2019	1	($0.09)	($0.09)	($0.09)
Q3 2019	1	($0.09)	($0.09)	($0.09)
Q4 2019	1	($0.06)	($0.06)	($0.06)

ArQule (NASDAQ ARQL) Earnings History by Quarter

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
5/1/2018		($0.07)					N/A
3/5/2018	Q4 2017	($0.09)	($0.09)			View	Listen
11/9/2017	Q3 2017	($0.11)	($0.09)			View	N/A
8/4/2017	Q2 2017	($0.11)	($0.10)			View	N/A
5/3/2017	Q1 2017	($0.1070)	($0.11)			View	Listen
3/7/2017	Q4 2016	($0.10)	($0.10)	$1.20 million	$1.19 million	View	Listen
11/7/2016	Q316	($0.09)	($0.08)	$1.10 million	$1.22 million	View	Listen
8/3/2016	Q216	($0.08)	($0.07)	$1.13 million	$1.07 million	View	N/A
5/4/2016	Q116	($0.07)	($0.08)	$1.63 million	$1.28 million	View	N/A
2/29/2016	Q415	($0.06)	($0.05)	$2.40 million	$2.80 million	View	Listen
11/4/2015	Q315	($0.08)	($0.04)	$2.60 million	$2.65 million	View	N/A
8/5/2015	Q215	($0.08)	($0.06)	$2.50 million	$3.04 million	View	N/A
5/6/2015	Q115	($0.08)	($0.07)	$1.98 million	$2.79 million	View	N/A
3/4/2015	Q414	($0.13)	($0.06)	$1.90 million	$3.02 million	View	N/A
11/10/2014	Q314	($0.13)	($0.10)	$2.20 million	$2.66 million	View	N/A
8/5/2014	Q214	($0.13)	($0.10)	$2.43 million	$2.90 million	View	N/A
5/7/2014	Q114	($0.11)	($0.11)	$2.29 million	$2.67 million	View	N/A
3/5/2014	Q413	($0.13)	($0.10)	$2.27 million	$2.28 million	View	N/A
10/31/2013	Q313	($0.13)	($0.10)	$2.77 million	$3.50 million	View	N/A
7/30/2013	Q2 2013	($0.12)	($0.11)	$3.84 million	$4.44 million	View	N/A
5/8/2013	Q1 2013	($0.11)	($0.09)	$3.78 million	$5.66 million	View	N/A
3/14/2013	Q4 2012	($0.13)	($0.09)	$5.17 million	$5.14 million	View	N/A
11/1/2012		($0.07)	($0.01)			View	N/A
8/2/2012		($0.07)	($0.01)			View	N/A
5/3/2012		($0.07)	($0.08)			View	N/A
3/1/2012		($0.09)	$0.07			View	N/A
11/10/2011		($0.23)	($0.04)			View	N/A
8/4/2011		($0.19)	($0.20)			View	N/A
5/5/2011		($0.08)	($0.03)			View	N/A
3/1/2011		($0.15)	($0.13)			View	N/A
11/9/2010	Q3 2010	($0.19)	($0.14)			View	N/A
8/4/2010	Q2 2010	($0.20)	($0.18)			View	N/A
5/6/2010	Q1 2010	($0.21)	($0.22)			View	N/A
3/2/2010	Q4 2009	($0.25)	($0.22)			View	N/A
11/5/2009	Q3 2009	($0.26)	($0.19)			View	N/A
8/6/2009	Q2 2009	($0.23)	($0.22)			View	N/A
5/7/2009	Q1 2009	($0.21)	($0.23)			View	N/A
3/5/2009	Q4 2008	($0.27)	($0.22)			View	N/A
11/10/2008	Q3 2008	($0.42)	($0.26)			View	N/A
8/11/2008	Q2 2008	($0.38)	($0.37)			View	N/A
5/12/2008	Q1 2008	($0.35)	($0.32)			View	N/A
2/7/2008	Q4 2007	($0.31)	($0.33)			View	N/A

(Earnings results data provided by Zacks Investment Research)

ArQule (NASDAQ:ARQL) Dividend History by Quarter

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date

(Data available from 1/1/2013 forward)

ArQule (NASDAQ ARQL) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 7.90%
Institutional Ownership Percentage: 67.17%

Insider Trading History for ArQule (NASDAQ:ARQL)

Institutional Ownership by Quarter for ArQule (NASDAQ:ARQL)

ArQule (NASDAQ ARQL) Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
4/18/2018	Value Fund L P Biotechnology	Insider	Sell	2,230,373	$3.10	$6,914,156.30
4/4/2018	Value Fund L P Biotechnology	Insider	Sell	2,301,581	$2.90	$6,674,584.90
9/7/2017	Paolo Pucci	CEO	Buy	1,101	$1.15	$1,266.15	404,194
9/6/2017	Paolo Pucci	CEO	Buy	16,397	$1.15	$18,856.55	403,093
9/5/2017	Paolo Pucci	CEO	Buy	19,156	$1.14	$21,837.84	386,696
8/29/2017	Paolo Pucci	CEO	Buy	300	$1.05	$315.00	367,540
8/28/2017	Paolo Pucci	CEO	Buy	2,970	$1.05	$3,118.50	367,240
8/25/2017	Paolo Pucci	Insider	Buy	9,492	$1.05	$9,966.60	363,569
12/17/2015	Michael D Loberg	Director	Buy	3,719	$2.16	$8,033.04	132,142
12/16/2015	Michael D Loberg	Director	Buy	1,231	$2.14	$2,634.34	128,423
12/15/2015	Paolo Pucci	CEO	Buy	1,283	$2.16	$2,771.28	257,280
12/11/2015	Paolo Pucci	CEO	Buy	1,108	$2.10	$2,326.80	255,997
12/11/2015	Patrick J Zenner	Director	Buy	2,300	$2.15	$4,945.00
12/10/2015	Paolo Pucci	CEO	Buy	7,609	$2.10	$15,978.90	254,889
3/11/2015	Patrick J Zenner	Director	Buy	10,625	$2.32	$24,650.00
11/20/2014	Paolo Pucci	CEO	Buy	5,000	$1.26	$6,300.00
11/14/2014	Patrick J Zenner	Director	Buy	20,830	$1.20	$24,996.00
11/13/2014	Susan L Kelley	Director	Buy	50,000	$1.20	$60,000.00
9/4/2014	Paolo Pucci	CEO	Buy	5,000	$1.31	$6,550.00
5/23/2014	Paolo Pucci	CEO	Buy	5,000	$1.40	$7,000.00
5/20/2014	Paolo Pucci	CEO	Buy	5,000	$1.42	$7,100.00	232,280
3/17/2014	Patrick Zenner	Director	Buy	4,715	$2.12	$9,995.80
3/13/2014	Paolo Pucci	CEO	Buy	10,000	$2.10	$21,000.00	227,280

(Data available from 1/1/2013 forward)

ArQule (NASDAQ ARQL) News Headlines

Source:

Date	Headline
	ArQule (ARQL) Lowered to "Hold" at Zacks Investment Research www.americanbankingnews.com - April 24 at 5:22 PM
	ArQule (ARQL) Set to Announce Earnings on Tuesday www.americanbankingnews.com - April 24 at 8:04 AM
	ArQule to Report First Quarter 2018 Financial Results on May 7, 2018 finance.yahoo.com - April 23 at 4:55 PM
	Leerink Swann Analysts Decrease Earnings Estimates for ArQule, Inc. (ARQL) www.americanbankingnews.com - April 23 at 1:22 AM
	$2.27 Million in Sales Expected for ArQule, Inc. (ARQL) This Quarter www.americanbankingnews.com - April 21 at 4:50 AM
	Insider Selling: ArQule, Inc. (ARQL) Insider Sells 2,230,373 Shares of Stock www.americanbankingnews.com - April 20 at 7:22 PM
	ArQule, Inc. (ARQL) Expected to Announce Earnings of -$0.06 Per Share www.americanbankingnews.com - April 19 at 9:09 AM
	ArQule (ARQL) PT Raised to $6 at Roth Capital, 'A Cleaner Story Going Forward' www.streetinsider.com - April 18 at 8:45 AM
	ArQule, Inc. (ARQL) Receives Consensus Recommendation of "Buy" from Brokerages www.americanbankingnews.com - April 18 at 3:38 AM
	Health Care Sector Update for 04/17/2018: ARQL,NCVR,JNJ,CLVS www.nasdaq.com - April 17 at 5:31 PM
	ArQule (ARQL) Price Target Raised to $6.00 www.americanbankingnews.com - April 17 at 1:23 PM
	Biotech Forum: The Week Ahead seekingalpha.com - April 17 at 9:04 AM
	BRIEF-Arqule And Basilea Enter Into Exclusive License Agreement For Derazantinib www.reuters.com - April 17 at 9:04 AM
	Basilea licenses late-stage oncology drug candidate derazant www.lse.co.uk - April 17 at 9:04 AM
	ArQule and Basilea Enter into Exclusive License Agreement for Derazantinib in the US, EU, Japan and Rest of World Excluding Greater China finance.yahoo.com - April 17 at 9:04 AM
	Basilea licenses late-stage oncology drug candidate derazantinib from ArQule feeds.benzinga.com - April 17 at 1:51 AM
	ArQule (ARQL) Upgraded by Zacks Investment Research to "Buy" www.americanbankingnews.com - April 16 at 6:30 PM
	ArQule, Inc. Is Moving On ASCO Release, Here’s Why. finance.yahoo.com - April 16 at 5:01 PM
	ArQule (ARQL) Downgraded to "Hold" at Zacks Investment Research www.americanbankingnews.com - April 13 at 5:29 PM
	Bristol-Myers Investors Set Their Sights on Next Week's Cancer Drug Showdown www.bloomberg.com - April 12 at 5:09 PM
	ArQule, Inc. (ARQL) to Post Q1 2018 Earnings of ($0.05) Per Share, Leerink Swann Forecasts www.americanbankingnews.com - April 9 at 1:39 AM
	ArQule (ARQL) Downgraded by BidaskClub to Buy www.americanbankingnews.com - April 7 at 7:02 AM
	ArQule, Inc. (ARQL) Insider Sells $6,674,584.90 in Stock www.americanbankingnews.com - April 6 at 7:14 PM
	ArQule (ARQL) Upgraded at Zacks Investment Research www.americanbankingnews.com - April 6 at 5:52 PM
	ArQule (ARQL) Stock Rating Upgraded by Leerink Swann www.americanbankingnews.com - April 5 at 12:27 PM
	Will ArQule (ARQL) Continue to Surge Higher? April 02, 2018 www.zacks.com - April 2 at 5:05 PM
	Will ArQule (ARQL) Continue to Surge Higher? finance.yahoo.com - April 2 at 9:10 AM
	Analysts Anticipate ArQule, Inc. (ARQL) Will Announce Earnings of -$0.06 Per Share www.americanbankingnews.com - April 2 at 7:28 AM
	ArQule (ARQL) Upgraded to Buy at Zacks Investment Research www.americanbankingnews.com - March 30 at 5:40 PM
	ArQule, Inc. (ARQL) Short Interest Up 128.8% in March www.americanbankingnews.com - March 30 at 2:27 AM
	Research Analysts Issue Forecasts for ArQule, Inc.'s Q2 2018 Earnings (ARQL) www.americanbankingnews.com - March 28 at 7:01 AM
	ArQule, Inc. (ARQL) to Post Q1 2019 Earnings of ($0.10) Per Share, B. Riley Forecasts www.americanbankingnews.com - March 27 at 7:52 AM
	ArQule (ARQL) Given a $4.00 Price Target at B. Riley www.americanbankingnews.com - March 26 at 1:24 PM
	BidaskClub Upgrades ArQule (ARQL) to Strong-Buy www.americanbankingnews.com - March 24 at 10:59 AM
	ArQule, Inc. (ARQL) Given Consensus Recommendation of "Buy" by Brokerages www.americanbankingnews.com - March 24 at 3:48 AM
	ArQule (ARQL) Rating Lowered to Hold at Zacks Investment Research www.americanbankingnews.com - March 21 at 4:40 PM
	Cytokinetics (CYTK) vs. ArQule (ARQL) Head-To-Head Comparison www.americanbankingnews.com - March 21 at 10:38 AM
	ArQule (ARQL) Upgraded to "Buy" by Zacks Investment Research www.americanbankingnews.com - March 20 at 5:56 PM
	ArQule to Present at the 17th Annual Needham Healthcare Conference on March 27, 2018 finance.yahoo.com - March 20 at 9:00 AM
	ArQule, Inc. (ARQL) Expected to Announce Quarterly Sales of $1.90 Million www.americanbankingnews.com - March 18 at 8:06 AM
	ArQule (ARQL) in Focus: Stock Moves 15.6% Higher finance.yahoo.com - March 16 at 6:04 PM
	FDA's BTD tag for J&J's erdafitinib stokes buying in competitor ArQule; shares up 12% seekingalpha.com - March 16 at 3:43 PM
	ArQule to Present Data at the 2018 American Association for Cancer Research (AACR) Annual Meeting - Business Wire (press release) www.businesswire.com - March 16 at 8:53 AM
	Analysts Anticipate ArQule, Inc. (ARQL) to Announce -$0.06 EPS www.americanbankingnews.com - March 16 at 5:16 AM
	ArQule (ARQL) Stock Rating Upgraded by ValuEngine www.americanbankingnews.com - March 16 at 12:48 AM
	ArQule to Present Data at the 2018 American Association for Cancer Research (AACR) Annual Meeting finance.yahoo.com - March 15 at 8:42 AM
	FY2018 Earnings Estimate for ArQule, Inc. Issued By Leerink Swann (ARQL) www.americanbankingnews.com - March 8 at 9:27 AM
	ArQule, Inc. (ARQL) Expected to Post Q1 2018 Earnings of ($0.05) Per Share www.americanbankingnews.com - March 7 at 7:58 AM
	ArQule Reports Fourth Quarter and Full Year 2017 Financial Results finance.yahoo.com - March 5 at 5:32 PM
	ArQule to Present at the 30th Annual Roth Conference on March 12, 2018 finance.yahoo.com - March 5 at 5:32 PM

ArQule (NASDAQ:ARQL) SEC Filings

Form Type:

Ownership Filings:

This page is loading this company's SEC Filings. Please wait...

ArQule (NASDAQ:ARQL) Income Statement, Balance Sheet and Cash Flow Statement

ArQule (NASDAQ ARQL) Stock Chart for Wednesday, April, 25, 2018

Loading chart…

This page was last updated on 4/25/2018 by MarketBeat.com Staff